United Kingdom based
Cytox Group Limited provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease and dementia. Cytox’s mission is to transform how new treatments are developed, people are screened, and how patients are managed within the Alzheimer’s disease care pathway..
TechnologiesAI Companies (Drug Discovery)
Cytox’s aim is to identify genetic risk variants, or single nucleotide polymorphisms (SNPs), which can be used ultimately, in the definition of an algorithm to predict AD progression.
No pipelines published yet
No services posted yet